Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway Sells 2,380 Shares

Artivion, Inc. (NYSE:AORTGet Free Report) SVP Jean F. Holloway sold 2,380 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $18.72, for a total transaction of $44,553.60. Following the sale, the senior vice president now owns 169,669 shares in the company, valued at $3,176,203.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Artivion Price Performance

Artivion stock opened at $19.75 on Friday. The firm has a market cap of $813.70 million, a PE ratio of -26.33 and a beta of 1.66. Artivion, Inc. has a 52-week low of $11.60 and a 52-week high of $20.49. The company has a quick ratio of 3.43, a current ratio of 4.85 and a debt-to-equity ratio of 1.10. The company’s 50 day moving average is $18.35 and its two-hundred day moving average is $16.65.

Artivion (NYSE:AORTGet Free Report) last released its earnings results on Thursday, February 15th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.24. Artivion had a negative net margin of 8.67% and a positive return on equity of 3.02%. The company had revenue of $93.67 million for the quarter, compared to analyst estimates of $89.75 million. On average, research analysts expect that Artivion, Inc. will post 0.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Artivion

Hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its holdings in shares of Artivion by 89.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,677 shares of the company’s stock valued at $29,000 after purchasing an additional 791 shares in the last quarter. Captrust Financial Advisors acquired a new stake in shares of Artivion in the 2nd quarter valued at $39,000. Money Concepts Capital Corp acquired a new stake in shares of Artivion in the 4th quarter valued at $28,000. Quantbot Technologies LP acquired a new stake in shares of Artivion in the 2nd quarter valued at $47,000. Finally, State of Wyoming raised its holdings in shares of Artivion by 207.1% in the 4th quarter. State of Wyoming now owns 3,495 shares of the company’s stock valued at $42,000 after purchasing an additional 2,357 shares in the last quarter. 83.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on AORT shares. Stifel Nicolaus increased their target price on shares of Artivion from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Needham & Company LLC increased their target price on shares of Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, February 16th.

View Our Latest Stock Analysis on Artivion

About Artivion

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

See Also

Insider Buying and Selling by Quarter for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.